This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
ActiveMax® Human Erythropoietin / EPO Protein, Tag Free
catalog :
EPO-H4214
quantity :
20 ug, 50 ug, 1 mg
price :
198 USD, 350 USD, 1571 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
EPO-H4214
product name :
ActiveMax® Human Erythropoietin / EPO Protein, Tag Free
quantity :
20 ug, 50 ug, 1 mg
price :
198 USD, 350 USD, 1571 USD
quantity & price :
$198/20ug,$350/50ug,$1571/1mg
target :
Erythropoietin
host species :
Human
By Tag :
Tag Free
Research :
For Research Use Only
Source :
ActiveMax® Human EPO, Tag Free (EPO-H4214) is expressed from human 293 cells (HEK293). It contains AA Ala 28 - Arg 193 (Accession # AAH93628.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>97% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
ActiveMax® Human EPO, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 97%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Human Erythropoietin (EPO) is also known as EP, erythropoetin or erthropoyetin, and is a glycoprotein hormone that controls erythropoiesis, or red blood cell production. EPO is a cytokine for erythrocyte (red blood cell) precursors in the bone marrow. is synthesized by renal peritubular cells in adults, with a small amount being produced in the liver. Regulation is believed to rely on a feed-back mechanism measuring blood oxygenation. Constitutively synthesized transcription factors for EPO, known as hypoxia-inducible factors (HIFs), are hydroxylated and proteosomally digested in the presence of oxygen. It binds to the erythropoietin receptor (EpoR) on the red cell surface and activates a JAK2 cascade. Erythropoietin has its primary effect on red blood cells by promoting red blood cell survival through protecting these cells from apoptosis. It also cooperates with various growth factors involved in the development of precursor red cells. EPO has a range of actions including vasoconstriction-dependent hypertension, stimulating angiogenesis, and inducing proliferation of smooth muscle fibers. It has also been shown that erythropoietin can increase iron absorption by suppressing the hormone hepcidin. Erythropoietin has been shown to interact with the Erythropoietin receptor as its mechanism of action within the body. erythropoietin plays an important role in the brain's response to neuronal injury. EPO is also involved in the wound healing process.
References :
(1) Jacobson LO, et al., 1957, Nature 179 (4560): 633–4.
(2) Fisher JW, et al., 1996, British journal of haematology 95 (1): 27–32.
(3) Jelkmann W ., 2007, Eur. J. Haematol. 78 (3): 183–205.
(4) Ashby DR, et al., 2010, Haematologica 95 (3): 505–8.
(5) Middleton S A., 1999, J. Biol. Chem. (UNITED STATES) 274 (20): 14163–9.
(6) Haroon ZA, et al., 2003, Am. J. Pathol. 163 (3): 993–1000.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments